Drugs / 89Zr-DFO-Nimotuzumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04235114 | Feb 2020 → Sep 2026 overdue | colorectal cancer, lung cancer | University of Saskatchewan | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-DFO-Nimotuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04235114 ↗ |
| Route | Intravenous | “will be injected intravenously” NCT04235114 ↗ |
| Target | EGFR | “imaging cancers that express EGFR using 89Zr-DFO-nimotuzumab” NCT04235114 ↗ |